Viyash Scientific allotted 6,12,773 new equity shares under ESOPs, at Rs. 86 and Rs. 101 per share. This action increased the total paid-up equity capital to ~Rs. 88.10 Cr, slightly diluting existing shareholders.
Viyash Scientific reported strong Q1 results with revenue up 19.5%, EBITDA soaring 59.2%, and PAT more than doubling. Acquisition of Bio For Life enhances presence in companion animal segment.
Viyash Scientific will allot equity shares to employees under ESOPs. The company is also incorporating a subsidiary in Vietnam and investing up to ₹400 crore in its wholly-owned subsidiary, Alivira Animal Health, through a rights issue to strengthen its capital structure.
Viyash Scientific has allotted 20,01,336 equity shares under its ESOP plan at Rs. 86 per share. This increases paid-up capital to Rs. 87.78 Cr, comprising 43.89 Cr shares.
Viyash Scientific's subsidiary has executed a purchase agreement to acquire 100% of BioForLife Italia s.r.l. for approximately EUR 16.98 million, with revised deferred consideration terms.
